Journal Basic Info

  • Impact Factor: 2.709**
  • H-Index: 11 
  • ISSN: 2474-1663
  • DOI: 10.25107/2474-1663
**Impact Factor calculated based on Google Scholar Citations. Please contact us for any more details.

Major Scope

  •  Paediatric Cancers
  •  Thoracic Oncology
  •  Pancreatic Cancer
  •  Colon Cancer
  •  Chemotherapy and Radiotherapy
  •  Kidney Cancer
  •  Stomach Cancer
  •  Ovarian Cancer

Abstract

Citation: Clin Oncol. 2021;6(1):1874.DOI: 10.25107/2474-1663.1874

NLRP3 Inflammasome Enhances Tumor Growth

Bernhard Ryffel

Laboratory of Experimental and Molecular Immunology and Neurogenetics (INEM), UMR 7355 CNRS-University of Orleans, Orleans, France

*Correspondance to: Bernhard Ryffel 

 PDF  Full Text Mini Review | Open Access

Abstract:

Tumor cell derived danger signals known as DAMPs activate the NLRP3 inflammasome leading to IL-1β/IL-18 production conferring a pro-inflammatory environment. The inflammatory tumor environment enhances the tumor progression and metastasis. The NLRP3 inflammasome or IL-1/IL-18 represents promising therapeutic targets in cancer therapy, which is discussed in this
review. Alternative targets such TLRs and cGAS/STING dependent immune regulators need to be considered. The metabolome and microbiome of the host are additional factors contributing to a successful chemo- and immunotherapy.

Keywords:

Cite the Article:

Ryffel B. NLRP3 Inflammasome Enhances Tumor Growth. Clin Oncol. 2021;6:1874..

Search Our Journal

Journal Indexed In

Articles in PubMed

LINGO-1 is a New Therapy Target and Biomarker for Ewing Sarcoma
 PubMed  PMC  PDF  Full Text
NMR Metabolomics in Ionizing Radiation
 PubMed  PMC  PDF  Full Text
View More...

Articles with Grants

Absolute dPCR Quantification of MicroRNAs by Absolute dPCR for the Diagnostic Screening of Colon Cancer
 PDF  Full Text
Impact of Cytotoxic T Lymphocytes Immunotherapy on Prognosis of Colorectal Cancer Patients
 Abstract  PDF  Full Text
View More...